The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe \[EU\] and Canada \[CAN\]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time from Solid Organ Transplant (SOT) Until Start Date of the Symptomatic or Asymptomatic Index Episode
Timeframe: From SOT up to start date of the index episode (Up to 7 years 3 months)
Percentage of Participants who are Asymptomatic and Symptomatic at the Index and Recurrent Episodes
Timeframe: Up to 7 years 3 months
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at the Index Episode and for Recurrent Episodes
Timeframe: Up to 7 years 3 months
Time From Start of Index Episode to CMV Viremia Clearance as Defined by Site Investigator
Timeframe: From start of index episode to CMV viremia clearance (Up to 7 years 3 months)
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at Week 8 After Index Date
Timeframe: At Week 8 after index date
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at Week 20 After Index Date
Timeframe: At Week 20 after index date
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at 1-year After Index Date
Timeframe: At 1-year after index date
Percentage of Participants With Non-detectable CMV During the Index Episode Prior to and After the Index Date
Timeframe: Up to 7 years 3 months
Percentage of Participants With Evidence of Non-detectable CMV at Week 8 After Index Date
Timeframe: At Week 8 after index date
Percentage of Participants With Evidence of Non-detectable CMV at Week 20 After Index Date
Timeframe: At Week 20 after index date
Percentage of Participants With Evidence of Non-detectable CMV at 1-year After Index Date
Timeframe: At 1-year after index date
Time From Treatment Initiation to CMV Viremia Clearance as Defined by Site Investigator at the Index Episode
Timeframe: From Treatment Initiation to CMV Viremia Clearance (Up to 7 years 3 months)
Time From Treatment Initiation Until Evidence of Non-detectable CMV at the Index Episode
Timeframe: Time from treatment initiation until evidence of non-detectable CMV (Up to 7 years 3 months)
Time from Start of Index Episode to First Symptomatic CMV Diagnosis
Timeframe: From start of index episode to first symptomatic CMV diagnosis (Up to 7 years 3 months)
Time From Stop Date of the Index Episode to First Recurrent Asymptomatic and Symptomatic CMV Viremia
Timeframe: From stop date of the index episode to first recurrent asymptomatic and symptomatic CMV viremia (Up to 7 years 3 months)
Percentage of Participants With Anti-CMV Treatment-related Myelosuppression and Nephrotoxicity
Timeframe: Up to 7 years 3 months
Percentage of Participants With Organ Rejection From SOT
Timeframe: Up to 7 years 3 months
Percentage of Participants With Graft Loss From SOT and the Index Date
Timeframe: Up to 7 years 3 months
Percentage of Participants who Died due to any Cause From SOT and Index Date
Timeframe: Up to 7 years 3 months
Percentage of Participants who Died due to CMV Infection From SOT and Index Date
Timeframe: Up to 7 years 3 months
Number of Genetic Mutations Conferring Anti-CMV Resistance From SOT and Index Date
Timeframe: Up to 7 years 3 months
Percentage of Participants With a Genetic Mutation Conferring Anti-CMV Resistance From SOT at the Index Date
Timeframe: Up to 7 years 3 months